SCHEMBL21887785

SCHEMBL21887785

CCCC(=O)N[C@@H](C)C(N)=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSD P07339 1/20 0.48
HDAC3 O15379 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
FAAH O00519 4/20 0.44
MEN1 O00255 1/20 0.44
MAPK1 P28482 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.39
SLC6A5 Q9Y345 1/20 0.39
DNM1 Q05193 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA9 Q16790 1/20 0.38
PSMB5 P28074 1/20 0.38
PRSS1 P07477 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4780586 1.00 CTSD (0.48) CTSDHDAC3HDAC1HDAC2HDAC8
SCHEMBL16658608 0.88 FAAH (0.55) FAAHMEN1MAPK1KMT2ASMN1; SMN2
SCHEMBL5983514 0.86 FAAH (0.63) FAAHMEN1MAPK1KMT2ASMN1; SMN2
SCHEMBL9666212 0.86 FAAH (0.63) FAAHMEN1MAPK1KMT2ASMN1; SMN2
SCHEMBL9666241 0.84 FAAH (0.67) FAAHMEN1MAPK1KMT2ASMN1; SMN2
SCHEMBL9666209 0.84 FAAH (0.67) FAAHMEN1MAPK1KMT2ASMN1; SMN2
SCHEMBL9664202 0.84 FAAH (0.67) FAAHMEN1MAPK1KMT2ASMN1; SMN2
SCHEMBL21587875 0.84 FAAH (0.67) FAAHMEN1MAPK1KMT2ASMN1; SMN2
SCHEMBL9665588 0.84 FAAH (0.67) FAAHMEN1MAPK1KMT2ASMN1; SMN2
SCHEMBL7519265 0.84 FAAH (0.67) FAAHMEN1MAPK1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220387608-A1 ADRENOMEDULLIN-ANALOGUES FOR LONG-TERM STABILIZATION AND THEIR USE BAYER AKTIENGESELLSCHAFT (DE) 2022-12-08 US disclosed
US-10676780-B2 Stabilisation and isolation of extracellular nucleic acids QIAGEN GMBH (DE) 2020-06-09 US disclosed
US-10597425-B2 Anti-GP41 antibody-specific capture agents, compositions, and methods of using and making CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2020-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220387608-A1 ADRENOMEDULLIN-ANALOGUES FOR LONG-TERM STABILIZATION AND THEIR USE VEGFA, ADM2, SERPINA6 CTSD 1488/4885HDAC3 4796/4885HDAC1 4713/4885
US-10597425-B2 Anti-GP41 antibody-specific capture agents, compositions, and methods of using and making CD81, CD4, FCGR3B CTSD 1169/4885HDAC3 4612/4885HDAC1 4786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.